From the *Department of Child and Adolescent Psychiatry, Central Institute of Mental Health, Mannheim, University of Heidelberg, Heidelberg; †Vitos Hospital for Psychiatry and Psychotherapy, Weilmuenster; ‡Lilly Deutschland GmbH, Medical Department, Bad Homburg, Germany; §Department of Psychology, Karlstad University, Sweden; ∥Department of Child and Adolescent Psychiatry, University of Cologne, Cologne; and ¶Eli Lilly Endowed Chair of Pediatric Psychopharmacology at the Department of Child and Adolescent Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
Received April 4, 2011; accepted after revision February 8, 2012.
Reprints: Peter M. Wehmeier, MD, Department of Child and Adolescent Psychiatry, Central Institute of Mental Health, PO Box 12 21 20, 68072 Mannheim, Germany (e-mail: [email protected]; [email protected]).
The study was funded by Lilly Deutschland, the German affiliate of Eli Lilly and Company.
Drs Wehmeier and Schacht equally contributed to this study and are both first authors.